GLYC GlycoMimetics Inc.

13
+0.15  (+1%)
Previous Close 12.85
Open 12.86
Price To Book 2.92
Market Cap 561,355,197
Shares 43,181,169
Volume 66,345
Short Ratio
Av. Daily Volume 265,916

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2020.
Uproleselan (GMI-1271)
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 3 data due 2H 2019 (possibly July/August)
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 1 ongoing.
GMI-1271
Multiple myeloma
Proof of concept trial to be initiated 2H 2019.
GMI-1359
Hormone receptor positive metastatic breast cancer
Phase 3 commencement of enrolment announced April 23, 2019.
Uproleselan (GMI-1271) - NCI
Acute myeloid leukemia (AML)

Latest News

  1. GlycoMimetics to Present at Jefferies 2019 Healthcare Conference
  2. Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT
  3. Here’s What Hedge Funds Think About GlycoMimetics, Inc. (GLYC)
  4. GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
  5. GlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript
  6. GlycoMimetics: 1Q Earnings Snapshot
  7. GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights
  8. GlycoMimetics, Inc. to Host Earnings Call
  9. GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
  10. GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019
  11. GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
  12. GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
  13. Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT
  14. GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
  15. GlycoMimetics to Present at Upcoming Investor Conferences
  16. GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
  17. Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares?
  18. GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript
  19. GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results